Keros Therapeutics, Inc. Payments of Financing Costs
Keros Therapeutics, Inc. (KROS) reported Payments of Financing Costs of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2022-03-09
- Keros Therapeutics, Inc. payments of financing costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Keros Therapeutics, Inc. payments of financing costs for fiscal 2020 was $420.00K.
- Keros Therapeutics, Inc. payments of financing costs for fiscal 2019 was $0.00.
| Period end | Payments of Financing Costs 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-09 |
| 2020-12-31 | $420.00K 10-K · filed 2022-03-09 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |